Recent actions by the Food and Drug Administration (FDA) to approve a new generic version of the abortion pill mifepristone under the Trump administration have drawn heavy criticism from some conservatives. The backlash stems from the view that the decision undermines the anti-abortion movement and increases access to abortion. Background on the generic drug approval On or around September 30, 2025, the FDA approved a generic version of mifepristone from the drugmaker Evita Solutions. Mifepristo

Overview of the USA FDA Classification Process

FDA Director-General, Resign Na — Sen. Raffy Tulfo Senator Raffy Tulfo called on the top officials of the Food and Drug Administration (FDA) to resign following what he described as serious lapses in the agency’s mandate to protect public health. Tulfo said the FDA leadership failed to act promptly on complaints and violations, putting consumers at risk. He stressed that accountability is necessary to restore public trust and ensure stronger enforcement of health and safety regulations. Video by